Eggermont AM - Search Results

1

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Among authors: eggermont am. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Clinical Trial.

2

Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.

Kruit WH, Goey SH, Monson JR, Stahel RA, Calabresi F, Mertelsmann R, Holdener EE, Eggermont AM, Bolhuis RL, de Mulder PH, et al. Kruit WH, et al. Among authors: eggermont am. Br J Haematol. 1991 Oct;79 Suppl 1:84-6. doi: 10.1111/j.1365-2141.1991.tb08128.x. Br J Haematol. 1991. PMID: 1931717

3

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, Oskam R, Bolhuis RL, Stoter G. Goey SH, et al. Among authors: eggermont am. Br J Cancer. 1995 Nov;72(5):1283-8. doi: 10.1038/bjc.1995.501. Br J Cancer. 1995. PMID: 7577483 Free PMC article. Clinical Trial.

4

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.

Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, Schmitz PI, Stoter G. Kruit WH, et al. Among authors: eggermont am. J Clin Oncol. 1993 May;11(5):921-4. doi: 10.1200/JCO.1993.11.5.921. J Clin Oncol. 1993. PMID: 8487055

5

A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb.

Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, van Dongen JA. Klaase JM, et al. Among authors: eggermont am. Cancer. 1993 May 15;71(10):2990-4. doi: 10.1002/1097-0142(19930515)71:10<2990::aid-cncr2820711017>3.0.co;2-6. Cancer. 1993. PMID: 8490826

6

Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources.

van Roozendaal KE, Klijn JG, van Ooijen B, Claassen C, Eggermont AM, Henzen-Logmans SC, Foekens JA. van Roozendaal KE, et al. Among authors: eggermont am. Int J Cancer. 1996 Jan 3;65(1):120-5. doi: 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J. Int J Cancer. 1996. PMID: 8543388

7

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

Kruit WH, Punt CJ, Goey SH, de Mulder PH, Gratama JW, Eggermont AM, Bolhuis RL, Stoter G. Kruit WH, et al. Among authors: eggermont am. Br J Cancer. 1996 Sep;74(6):951-5. doi: 10.1038/bjc.1996.463. Br J Cancer. 1996. PMID: 8826864 Free PMC article.

8

High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

Kruit WH, Goey SH, Lamers CH, Gratama JW, Visser B, Schmitz PI, Eggermont AM, Bolhuis RL, Stoter G. Kruit WH, et al. Among authors: eggermont am. J Immunother. 1997 Jul;20(4):312-20. doi: 10.1097/00002371-199707000-00008. J Immunother. 1997. PMID: 9220321 Clinical Trial.

9

Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats.

Schellens JH, Van de Vrie W, Loos WJ, Kolker HJ, Verweij J, Stoter G, Durante NM, Eggermont AM. Schellens JH, et al. Among authors: eggermont am. Cancer Chemother Pharmacol. 1997;41(1):48-52. doi: 10.1007/s002800050706. Cancer Chemother Pharmacol. 1997. PMID: 9443613

10

Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats.

van der Veen AH, Eggermont AM, Seynhaeve AL, van Tiel, ten Hagen TL. van der Veen AH, et al. Among authors: eggermont am. Int J Cancer. 1998 Sep 11;77(6):901-6. doi: 10.1002/(sici)1097-0215(19980911)77:6<901::aid-ijc17>3.0.co;2-3. Int J Cancer. 1998. PMID: 9714061

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

664 results

Search Page

Filters